Assessing cancer risk in the anterior part of the prostate using micro-ultrasound: validation of a novel distinct protocol - Summary - MDSpire

Assessing cancer risk in the anterior part of the prostate using micro-ultrasound: validation of a novel distinct protocol

  • By

  • Sandy Schaer

  • Arnas Rakauskas

  • Julien Dagher

  • Stefano La Rosa

  • Jake Pensa

  • Wayne Brisbane

  • Leonard Marks

  • Adam Kinnaird

  • Robert Abouassaly

  • Eric Klein

  • Lewis Thomas

  • Jean-Yves Meuwly

  • Pamela Parker

  • Beat Roth

  • Massimo Valerio

  • September 15, 2023

  • 0 min

Share

Objective:

To develop and validate a microUS risk score specifically for predicting significant prostate cancer in the anterior part of the prostate.

Key Findings:
  • Each increase in risk score correlates with a 10% increase in the probability of clinically significant cancer.
  • MicroUS features were identified that differentiate between benign and cancerous anterior prostate tissue.
  • Training material was developed to standardize the interpretation of microUS images among readers, enhancing diagnostic consistency.
Interpretation:

The PRI-MUS protocol can be adapted for the anterior part of the prostate, potentially improving cancer detection rates and influencing clinical decision-making.

Limitations:
  • Study limited to retrospective analysis and specific patient populations, which may affect the generalizability of the findings.
  • MicroUS evaluation currently only applicable to the anterior region and not validated for other areas.
Conclusion:

The study successfully developed a microUS risk score for the anterior prostate, which may enhance the detection of significant prostate cancer.

Original Source(s)

Assessing cancer risk in the anterior part of the prostate using micro-ultrasound: validation of a novel distinct protocol

  • by Sandy Schaer, Arnas Rakauskas, Julien Dagher, Stefano La Rosa, Jake Pensa, Wayne Brisbane, Leonard Marks, Adam Kinnaird, Robert Abouassaly, Eric Klein, Lewis Thomas, Jean-Yves Meuwly, Pamela Parker, Beat Roth, Massimo Valerio

  • September 15, 2023

Related Content

99mTc-HDP bone scintigraphy and 18F-sodiumfluoride PET/CT in primary staging of patients with prostate cancer

Head-to-head comparison of biparametric versus multiparametric MRI of the prostate before robot-assisted transperineal fusion prostate biopsy

Detection of prostate cancer with 18F-DCFPyL PET/CT compared to final histopathology of radical prostatectomy specimens: is PSMA-targeted biopsy feasible? The DeTeCT trial